Madrigal Pharmaceuticals (MDGL) Accounts Payables (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Accounts Payables data on file, last reported at $60.8 million in Q1 2026.

• On a quarterly basis, Accounts Payables rose 44.57% year-over-year to $60.8 million in Q1 2026; TTM through Mar 2026 was $60.8 million, a 44.57% increase from a year earlier, with the FY2025 full-year figure at $48.9 million, up 12.11% from the prior year.
• Accounts Payables for Q1 2026 stood at $60.8 million, up from $48.9 million in the prior quarter.
• Over the last five years, Accounts Payables for MDGL reached as high as $60.8 million in Q1 2026 and fell as low as $9.0 million in Q2 2024.
• Historically, Accounts Payables has averaged $29.7 million across 5 years, with a median of $23.8 million in 2022.
• Across the five-year window, Accounts Payables soared 958.48% in 2022 and sank 48.71% in 2024, its largest moves.
• Year by year, Accounts Payables stood at $23.8 million in 2022, then increased by 17.67% to $28.0 million in 2023, then jumped by 55.48% to $43.6 million in 2024, then increased by 12.11% to $48.9 million in 2025, then gained by 24.39% to $60.8 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $60.8 million in Q1 2026, $48.9 million in Q4 2025, and $44.9 million in Q3 2025.